D&H Cancer Research Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gerardo, Colon-Otero
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
Chacin, Alexander
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
NCT06315491: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Recruiting
2
60
US
CBX-12
Cybrexa Therapeutics
Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
04/26
07/26
LIGHTSPEED-1, NCT06277219: A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors

Recruiting
1/2
150
US
LAT010, LAT010 + ICI
Latticon Antibody Therapeutics, Inc
Advanced Solid Tumor
12/26
03/27
Vega, Angheli
LIGHTSPEED-1, NCT06277219: A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors

Recruiting
1/2
150
US
LAT010, LAT010 + ICI
Latticon Antibody Therapeutics, Inc
Advanced Solid Tumor
12/26
03/27
Linares, Camila
CTX-8371-001, NCT06150664: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Recruiting
1
55
US
CTX-8371
Compass Therapeutics
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
10/25
04/26

Download Options